Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

<i>Background and Objectives:</i> Patients with human epidermal growth factor receptor 2 (HER2) -positive, hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) usually undergo trastuzumab emtansine (T-DM1) therapy in subsequent lines. Combining endocrine therapy (ET) with T-DM1 can...

詳細記述

書誌詳細

主要な著者:	Oğuzcan Kınıkoğlu, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yıldırım, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yıldırım, Nedim Turan
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2024-06-01
シリーズ:	Medicina
主題:	metastatic breast cancer trastuzumab emtansine endocrine therapy pertuzumab plus trastuzumab
オンライン･アクセス:	https://www.mdpi.com/1648-9144/60/6/951
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!